Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Caracciolo

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
European Journal of Haematology|April 24, 2026
Regional Standardization of CLL Management: Results of a Delphi Consensus ProcessEnrica Antonia Martino, Annalisa Chiarenza, Salvatrice Mancuso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphomaCorrado Tarella, Roberto Passera, Michele Magni, et al.
Leukemia|July 8, 2020
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myelomaMarco Rossi, Emanuela Altomare, Cirino Botta, et al.
Blood|July 13, 2018
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92Eugenio Morelli, Lavinia Biamonte, Cinzia Federico, et al.
Cells|August 29, 2020
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced PneumonitisPierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
British Journal of Haematology|July 3, 2026
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experienceAndrea Duminuco, Dario Leotta, Alessandro Allegra, et al.
Life (Basel, Switzerland)|November 27, 2021
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional AnalysisValerio Nardone, Rocco Giannicola, Diana Giannarelli, et al.
Molecular Therapy. Nucleic Acids|March 14, 2022
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic reviewMaria Teresa Di Martino, Mariamena Arbitrio, Daniele Caracciolo, et al.
Cancers|June 24, 2022
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) CellsCaterina Riillo, Daniele Caracciolo, Katia Grillone, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockadePierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
European Journal of Haematology|April 24, 2026
Regional Standardization of CLL Management: Results of a Delphi Consensus ProcessEnrica Antonia Martino, Annalisa Chiarenza, Salvatrice Mancuso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2010
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphomaCorrado Tarella, Roberto Passera, Michele Magni, et al.
Leukemia|July 8, 2020
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myelomaMarco Rossi, Emanuela Altomare, Cirino Botta, et al.
Blood|July 13, 2018
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92Eugenio Morelli, Lavinia Biamonte, Cinzia Federico, et al.
Cells|August 29, 2020
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced PneumonitisPierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
British Journal of Haematology|July 3, 2026
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experienceAndrea Duminuco, Dario Leotta, Alessandro Allegra, et al.
Life (Basel, Switzerland)|November 27, 2021
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional AnalysisValerio Nardone, Rocco Giannicola, Diana Giannarelli, et al.
Molecular Therapy. Nucleic Acids|March 14, 2022
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic reviewMaria Teresa Di Martino, Mariamena Arbitrio, Daniele Caracciolo, et al.
Cancers|June 24, 2022
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) CellsCaterina Riillo, Daniele Caracciolo, Katia Grillone, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockadePierpaolo Correale, Rita Emilena Saladino, Diana Giannarelli, et al.
Pageof 8